Perampanel
Fycompa (perampanel) is a prescription medication that acts as a noncompetitive AMPA glutamate receptor antagonist to help control seizures in epilepsy patients. Available as oral tablets in strengths from 2mg to 12mg, it's manufactured by Catalyst Pharmaceuticals, Inc., and is a Schedule III controlled substance. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[ "009:10" ] |
| contactPoint |
{ "fn": "Division of Drug Information", "@type": "vcard:Contact", "hasEmail": "mailto:druginfo@fda.hhs.gov" } |
| description | Fycompa (perampanel) is a prescription medication that acts as a noncompetitive AMPA glutamate receptor antagonist to help control seizures in epilepsy patients. Available as oral tablets in strengths from 2mg to 12mg, it's manufactured by Catalyst Pharmaceuticals, Inc., and is a Schedule III controlled substance. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[ { "@type": "dcat:Distribution", "title": "Perampanel", "mediaType": "text/html", "description": " Access the FDA dataset for Perampanel — ANDA 202834 submitted by Mylan Institutional LLC ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202834" } ] |
| identifier | ANDA202834 |
| issued | 2016-09-16 |
| keyword |
[ "drug", "drug-safety", "fda", "prescription-drugs", "public-health" ] |
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[ "009:002" ] |
| publisher |
{ "name": "U.S. Food and Drug Administration", "@type": "org:Organization" } |
| theme |
[ "FDA" ] |
| title | Perampanel |
